BlackRock, Inc. filed Amendment No. 4 to its Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of 6,577,306 shares of BioLife Solutions Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported beneficial ownership of 6,577,306 shares of BioLife Solutions Inc. common stock, representing 13.4% of the class.
  • Sole voting power: BlackRock reported sole voting power over 6,461,043 shares.
  • Sole dispositive power: BlackRock reported sole dispositive power over 6,577,306 shares, with no shared dispositive power.
  • Five-percent beneficial holder identified: iShares Core S&P Small-Cap ETF was disclosed as holding more than 5% of BioLife Solutions' total outstanding common stock on behalf of another person.
  • Triggering event date: The filing was triggered by an event on September 30, 2026.
  • Reporting person type: BlackRock is classified as a parent holding company (type: HC), incorporated in Delaware.

BlackRock's Amendment No. 4 Ownership Position in BioLife Solutions

According to the filing, BlackRock, Inc., headquartered at 50 Hudson Yards, New York, NY 10001, submitted Amendment No. 4 to Schedule 13G covering its beneficial ownership of common stock (CUSIP 09062W204) in BioLife Solutions Inc., whose principal executive offices are located at 3303 Monte Villa Parkway, Suite 310, Bothell, Washington, 98021. The filing covers a triggering event dated September 30, 2026, and was signed by Spencer Fleming, Managing Director, on October 27, 2026.

The filing disclosed that BlackRock beneficially owned an aggregate of 6,577,306 shares, equating to 13.4% of the class. Of those shares, BlackRock reported sole voting power over 6,461,043 shares and sole dispositive power over the full 6,577,306 shares. Shared voting power and shared dispositive power were each reported as zero. The filing noted that the schedule reflects securities beneficially owned by certain business units of BlackRock and its subsidiaries and affiliates, and "does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units."

Under Item 6, the filing identified iShares Core S&P Small-Cap ETF as a person whose interest in BioLife Solutions common stock is more than five percent of the total outstanding common stock. BlackRock certified that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." Subsidiary identification details were referenced in Exhibit 99.

What Was Disclosed

BlackRock, Inc. filed Amendment No. 4 to Schedule 13G reporting 6,577,306 shares, or 13.4%, of BioLife Solutions Inc. common stock beneficially owned as of September 30, 2026, with sole voting power over 6,461,043 shares and iShares Core S&P Small-Cap ETF identified as a more-than-5% interest holder.